Anti-AFG3L2 antibody (ab241158)
Key features and details
- Rabbit polyclonal to AFG3L2
- Suitable for: WB, IP
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-AFG3L2 antibody
See all AFG3L2 primary antibodies -
Description
Rabbit polyclonal to AFG3L2 -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species IP HumanWB Human
-
Immunogen
Synthetic peptide within Human AFG3L2 aa 75-125. The exact sequence is proprietary.
Database link: Q9Y4W6 -
Positive control
- WB: HeLa, HEK-293T and Jurkat cell lysate. IP: HEK-293T cell lysate.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7
Preservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8 -
Concentration information loading... -
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Images
-
Western blot - Anti-AFG3L2 antibody (ab241158)All lanes : Anti-AFG3L2 antibody (ab241158) at 0.1 µg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) cell lysate
Lane 3 : Jurkat (human T cell leukemia cell line from peripheral blood) cell lysate
Lysates/proteins at 50 µg per lane.
Developed using the ECL technique.
Exposure time: 30 secondsPrepared using NETN lysis buffer.
-
Immunoprecipitation - Anti-AFG3L2 antibody (ab241158)AFG3L2 was immunoprecipitated from HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate (1 mg for IP, 20% of IP loaded) with ab241158 at 6 µg/reaction. Western blot was performed from the immunoprecipitate using ab241158 at 0.4 µg/ml.
Lane 1: ab241158 IP in HEK-293T whole cell lysate.
Lane 2: Control IgG IP in HEK-293T whole cell lysate.Detection: Chemiluminescence with exposure time of 30 seconds.
